84 results about "Thromboembolic disorder" patented technology

Embolectomy catheters, rapid exchange microcatheters, systems and methods for removing clots or other obstructive matter (e.g., thrombus, thromboemboli, embolic fragments of atherosclerotic plaque, foreign objects, etc.) from blood vessels. This invention is particularly useable for percutaneous removal of thromboemboli or other obstructive matter from small blood vessels of the brain, during an evolving stroke or period of cerebral ischemia. In some embodiments, the embolectomy catheters of this invention are advanceable with or over a guidewire which has been pre-inserted through or around the clot. Also, in some embodiments, the embolectomy catheters include clot removal devices which are deployable from the catheter after the catheter has been advanced at least partially through the clot. The clot removal device may include a deployable wire nest that is designed to prevent a blood clot from passing therethrough. The delivery catheter may include telescoping inner and outer tubes, with the clot removal device being radially constrained by the outer tube. Retraction of the outer tube removes the constraint on the clot removal device and permits it to expand to its deployed configuration. An infusion guidewire is particularly useful in conjunction with the embolectomy catheter, and permits infusion of medicaments or visualization fluids distal to the clot.

This invention relates to novel compounds of formula (I)

or stereoisomers or pharmaceutically acceptable salts thereof wherein Y, R¹ through R⁹, and X¹ through X⁷ are as defined in the specification, pharmaceutical compositions containing said compounds useful as P2Y₁ antagonists, and to methods of treating thromboembolic disorders.

Compositions comprising crystalline apixaban particles having a D₉₀ equal to or less than 89 μm, and a pharmaceutically acceptable carrier, are substantially bioequivalent and can be used to for the treatment and/or prophylaxis of thromboembolic disorders.

The present invention relates to novel heterocyclic compounds of Formulae I-III; as disclosed herein or a pharmaceutically acceptable salt, solvate, ester, prodrug or stereoisomer thereof. Also disclosed are pharmaceutical compositions comprising said compounds, and methods for using said compounds for treating or preventing a thromboembolic disorder.

The present invention is directed to a therapeutic agent comprising a GPIIIa(49-66) specific targeting agent and a thrombi-specific homing agent. Also disclosed is the use of the therapeutic agent in carrying out a method of treating thromboembolic disorders and a method of inducing platelet fragmentation.

The present invention provides imidazothiadiazole compounds of Formula (I); Wherein W, Y, R⁰, R², R⁴, R^a, R^b, X¹, X², X³ and X⁴ are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug ester or solvate form thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of platelet aggregation and thus can be used as medicaments for treating or preventing thromboembolic disorders.

The present invention provides thiazole compounds of Formula I

wherein X, Y, Z, X¹, X², X³, X⁴, X⁵, R¹, R², R⁴, R⁵, R⁶, R⁷, and W, are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug, ester or solvate form thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of platelet aggregation and thus can be used as medicaments for treating or preventing thromboembolic disorders.

The present invention provides thiazole compounds of Formula I

wherein X¹, X², X³, X⁴, X⁵, R¹, R², R⁴, R⁵, R⁶, R⁷, and W, and ring AA, are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt, prodrugs, or esters or solvate form thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of platelet aggregation and thus can be used as medicaments for treating or preventing thromboembolic disorders.

The present invention relates to a pharmaceutical composition comprising apixaban, in particular to a pharmaceutical composition comprising apixaban and a polymer having low viscosity as binder, and to a process for its preparation. The pharmaceutical composition is particularly useful as a medicament, especially for the treatment or prevention of a thromboembolic disorder.

The use of activated protein C for the manufacture of a medicament for the treatment of vascular occlusive and thromboembolic disorders at a dose of about 0.01mg/kg/hr to about 0.05mg/kg/hr.

Novel compounds comprising a guanidine-rich head covalently coupled to one or more oligonucleotide antisense sequences which are useful to modulate blood coagulation by affecting the expression of integrin αIIb or β3 are described herein. This invention also includes pharmaceutical compositions containing these compounds, with or without other therapeutic agents, and to methods of using these compounds as inhibitor of platelet aggregation, as thrombolytics, and/or for the treatment of other thromboembolic disorders. Vivo-MOs, which include eight guanidine groups dendrimerically arranged in the guanidine-rich head and two synthetic antisense morpholino oligonucleotides, are representative compounds of the present invention.

Disclosed is a compound of Formula (I) or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate or prodrug thereof, wherein one R₃ is H and the other R₃ is an aryl group substituted with zero to 3 R_3a; and R₁, R₂, and R_3a are defined herein. Also disclosed are methods of using such compounds as PAR4 inhibitors for the inhibition or prevention of platelet aggregation, and the treatment of a thromboembolic disorder or the primary prophylaxis of a thromboembolic disorder. Also disclosed are methods of using such compounds for the treatment of human papillomavirus. Additionally, pharmaceutical compositions comprising at least one compound of Formula (I) are disclosed.

Disclosed are compounds of Formula (I) to (IV): [INSERT CHEMICAL STRUCTURE HERE] or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate or prodrug thereof. Also disclosed are methods of using such compounds as PAR4 inhibitors, and pharmaceutical compositions comprising such compounds. These compounds are useful in inhibiting or preventing platelet aggregation, and are useful for the treatment of a thromboembolic disorder or the primary prophylaxis of a thromboembolic disorder.

The invention relates to a pharmaceutical composition containing aspirin, clopidogrel and a folic acid compound. According to the pharmaceutical composition disclosed by the invention, the folic acid compound is prepared from the following components including folic acid, 5-methyltetrahydrofolic acid, formyl tetrahydrofolic acid, folinic acid, calcium levofolinate and medicinal salts of folic acid. The pharmaceutical composition is preferentially prepared from the following components by weight: 50-150mg of aspirin, 50-100mg of clopidogrel and 0.4-2mg of folic acid compound. The invention also relates to an application of the pharmaceutical composition in preparing a medicament for preventing a thromboembolic disease. With the adoption of the pharmaceutical composition, the medicament prepared from the pharmaceutical composition has a remarkable effect of inhibiting formation of thrombus on the basis of effectively inhibiting platelet aggregation; in addition, a patient is convenient to take the pharmaceutical composition, and compliance is improved.